Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and II Diabetic Nephropathy Trial (IDNT) trials
Primary result · Kidney outcome (ESKD or doubling of serum creatinine)Result — go to the resultSex × treatment interaction HR 1.19 95% CI 0.89–1.59Authors' conclusion
This study in individuals with type 2 diabetes and diabetic kidney disease suggests that the beneficial effects of angiotensin receptor blockers are similar in male and female participants for the kidney outcome but not for the cardiovascular outcome. More attention to sex differences in angiotensin receptor blockers' efficacy and underlying mechanisms of differences in response is needed.
Study context
- Population
- Individuals with T2D and diabetic kidney disease in the RENAAL and IDNT trials
- Participants
- 1,737 vs 924
- Comparison
- Angiotensin receptor blockers vs control, by sex
- Malen = 1,737
- Femalen = 924
- Primary endpoint
- Kidney outcome: time to first ESKD or doubling of serum creatinine; CV outcome: time to first stroke, MI, CV death or hospitalisation for HF
Methodological detailssubgroup analysis by sex, sex × treatment interaction in Cox proportional hazards models
- Subgroup analysis by sex
- Sex × treatment interaction in Cox proportional hazards models
Primary result
As reported in the abstract
Kidney outcome:
- ESKD
- Doubling of serum creatinine
Sex × treatment interaction HR
1.19
95% CI 0.89–1.59
By group
Male
0.72
95% CI 0.59, 0.86
HR (ARB vs control)
Female
0.86
95% CI 0.69, 1.06
HR (ARB vs control)
Femalevs Male
sex × treatment interaction HR 1.19 (95% CI 0.89–1.59)
Further findings
| Outcome | Male | Female | Sex × treatment interaction HR (95% CI) | |
|---|---|---|---|---|
| CV outcome (stroke, MI, CV death or hospitalisation for HF) | 1.37 (1.03–1.82) | |||
| HR (ARB vs control) | 0.81 [95% CI 0.69, 0.95] | 1.11 [95% CI 0.88, 1.40] | ||
| 0.512Sex × treatment interaction HR (log scale) |
CV outcome (stroke, MI, CV death or hospitalisation for HF)
- ARBs lowered CV risk in male but not in female participants
Original publication
Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials. Diabetologia. Published 10 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →